Print this page
-
NRG-GU012: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Protocol: 082305Principal Investigator:
- Lara Hathout MD (Rutgers University)
Applicable Disease Sites: Kidney -
A Phase 2 Study of Dabrafenib with Trametinib after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG).
Protocol: 112302Principal Investigator:
- Teena Bhatla (Newark Beth Israel Medical Center)
Applicable Disease Sites: Brain and Nervous System -
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Protocol: 112305Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Hodgkin's Lymphoma -
A Phase III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC.
Protocol: 032111Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG).
Protocol: 112203Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System -
A Phase II Study of Preoperative Pembrolizumab for Mismatch Repair Deficient, Epstein-Barr Virus Positive and/or PD-L1 Positive Gastric Cancer followed by Chemotherapy and Chemoradiation with Pembrolizumab.
Protocol: 071702Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Stomach